Literature DB >> 21753120

Drug effectiveness explained: the mathematics of antiviral agents for HIV.

Alan S Perelson1, Steven G Deeks.   

Abstract

Antiretroviral therapy has improved the quality and length of life of millions of individuals affected by human immunodeficiency virus type 1 (HIV-1). The capacity of these drugs to indefinitely suppress HIV-which has a well-known capacity for escaping antiviral pressures-is surprising. In this issue of Science Translational Medicine, Shen et al. use a combination of mathematical modeling and experiment to examine the potency of anti-HIV drugs. They show that non-nucleoside reverse transcriptase inhibitors and protease inhibitors exhibit cooperative dose-response curves-a finding that has implications for the treatment of HIV as well as other viral infections, such as hepatitis C.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21753120      PMCID: PMC3236558          DOI: 10.1126/scitranslmed.3002656

Source DB:  PubMed          Journal:  Sci Transl Med        ISSN: 1946-6234            Impact factor:   17.956


  21 in total

1.  Decline in the AIDS and death rates in the EuroSIDA study: an observational study.

Authors:  A Mocroft; B Ledergerber; C Katlama; O Kirk; P Reiss; A d'Arminio Monforte; B Knysz; M Dietrich; A N Phillips; J D Lundgren
Journal:  Lancet       Date:  2003-07-05       Impact factor: 79.321

Review 2.  Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies.

Authors:  Ting-Chao Chou
Journal:  Pharmacol Rev       Date:  2006-09       Impact factor: 25.468

3.  Rapid emergence of enfuvirtide resistance in HIV-1-infected patients: results of a clonal analysis.

Authors:  Jing Lu; Steven G Deeks; Rebecca Hoh; George Beatty; Benjamin A Kuritzkes; Jeffrey N Martin; Daniel R Kuritzkes
Journal:  J Acquir Immune Defic Syndr       Date:  2006-09       Impact factor: 3.731

4.  Pharmacodynamics of PEG-IFN alpha differentiate HIV/HCV coinfected sustained virological responders from nonresponders.

Authors:  Andrew H Talal; Ruy M Ribeiro; Kimberly A Powers; Michael Grace; Constance Cullen; Musaddeq Hussain; Marianthi Markatou; Alan S Perelson
Journal:  Hepatology       Date:  2006-05       Impact factor: 17.425

5.  Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection.

Authors:  John G McHutchison; Gregory T Everson; Stuart C Gordon; Ira M Jacobson; Mark Sulkowski; Robert Kauffman; Lindsay McNair; John Alam; Andrew J Muir
Journal:  N Engl J Med       Date:  2009-04-30       Impact factor: 91.245

6.  Class-sparing regimens for initial treatment of HIV-1 infection.

Authors:  Sharon A Riddler; Richard Haubrich; A Gregory DiRienzo; Lynne Peeples; William G Powderly; Karin L Klingman; Kevin W Garren; Tania George; James F Rooney; Barbara Brizz; Umesh G Lalloo; Robert L Murphy; Susan Swindells; Diane Havlir; John W Mellors
Journal:  N Engl J Med       Date:  2008-05-15       Impact factor: 91.245

7.  Nonrandom HIV-1 infection and double infection via direct and cell-mediated pathways.

Authors:  Que Dang; Jianbo Chen; Derya Unutmaz; John M Coffin; Vinay K Pathak; Douglas Powell; Vineet N KewalRamani; Frank Maldarelli; Wei-Shau Hu
Journal:  Proc Natl Acad Sci U S A       Date:  2004-01-05       Impact factor: 11.205

8.  The level of reverse transcriptase (RT) in human immunodeficiency virus type 1 particles affects susceptibility to nonnucleoside RT inhibitors but not to lamivudine.

Authors:  Zandrea Ambrose; John G Julias; Paul L Boyer; Vineet N Kewalramani; Stephen H Hughes
Journal:  J Virol       Date:  2006-03       Impact factor: 5.103

9.  A critical subset model provides a conceptual basis for the high antiviral activity of major HIV drugs.

Authors:  Lin Shen; S Alireza Rabi; Ahmad R Sedaghat; Liang Shan; Jun Lai; Sifei Xing; Robert F Siliciano
Journal:  Sci Transl Med       Date:  2011-07-13       Impact factor: 17.956

10.  Dose-response curve slope sets class-specific limits on inhibitory potential of anti-HIV drugs.

Authors:  Lin Shen; Susan Peterson; Ahmad R Sedaghat; Moira A McMahon; Marc Callender; Haili Zhang; Yan Zhou; Eleanor Pitt; Karen S Anderson; Edward P Acosta; Robert F Siliciano
Journal:  Nat Med       Date:  2008-06-15       Impact factor: 53.440

View more
  2 in total

1.  Efficacy and safety of danoprevir-ritonavir plus peginterferon alfa-2a-ribavirin in hepatitis C virus genotype 1 prior null responders.

Authors:  Edward J Gane; Régine Rouzier; Alicja Wiercinska-Drapalo; Dominique G Larrey; Peter N Morcos; Barbara J Brennan; Sophie Le Pogam; Isabel Nájera; Rosemary Petric; Jonathan Q Tran; Rohit Kulkarni; Ying Zhang; Patrick Smith; Ellen S Yetzer; Nancy S Shulman
Journal:  Antimicrob Agents Chemother       Date:  2013-12-02       Impact factor: 5.191

2.  Gag-Pol processing during HIV-1 virion maturation: a systems biology approach.

Authors:  Balázs Könnyű; S Kashif Sadiq; Tamás Turányi; Rita Hírmondó; Barbara Müller; Hans-Georg Kräusslich; Peter V Coveney; Viktor Müller
Journal:  PLoS Comput Biol       Date:  2013-06-06       Impact factor: 4.475

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.